UNSPSC 51141560: Etiracetam

This classification denotes an anticonvulsant agent with the molecular formula C8H14N2O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 230447L0GL, chemically known as 1-pyrrolidineacetamide, alpha-ethyl-2-oxo-, (s)- but generally known as etiracetam, which bears US NIH Compound Identifier 59708. European Medicines Agency schedules Etiracetam in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07308MIG.

UNSPSC 51141560 Etiracetam is a Commodity code for a specific pharmaceutical product, though the recent state and local procurement activity under this code does not reflect its nominal scope. State and local governments soliciting pharmaceuticals do buy medications for public health initiatives, community health programs, and emergency response — but the single recent opportunity posted under this code (Seminole County, Florida's IFB for naloxone and drug deactivation systems) involves procurement of naloxone and harm-reduction equipment, not etiracetam, a nootropic compound with limited public-sector use. The mismatch suggests either a data-entry error in the code assignment or minimal recent state and local demand for etiracetam specifically. Issuing bodies that do pursue pharmaceutical procurement at the state and local level typically include county health departments, city public health agencies, and special-purpose health districts, often with quarterly or annual replenishment cycles and fixed-fee pricing structures.

Seminole County, Florida represents the only recent activity in the dataset. The county released an IFB (IFB60459723LAS) on June 30, 2026, seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to the Seminole County Community Health Building in Sanford, Florida; the response deadline was July 26, 2023. The contract carried a two-year initial term with one-year renewal option, E-Verify compliance requirements, drug-free workplace certification, and potential FEMA funding with accompanying federal compliance obligations. The code shows no detectable recent etiracetam procurement activity from state or local jurisdictions, signaling either no current market demand or systematic miscoding of pharmaceutical solicitations at this tier.